As required by law, Axsome and Hikma will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S.

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has earned a consensus rating of “Buy” from the fifteen ratings ...

In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a price ...

Axsome Therapeutics (AXSM) stock gains as company settles patent dispute with Hikma (HKMPF) over sleep therapy Sunosi. Read ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective hoisted by stock analysts at Robert W. Baird from ...

Meeting to be held in New York on March 6 hosted by Piper Sandler.Discover the Best Stocks and Maximize Your Portfolio: See what stocks are ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome ...

TD Cowen 45th Annual Health Care Conference on March 4 in Boston Leerink Partners Global Biopharma Conference on March 12 in ...

Axsome Therapeutics, a biopharmaceutical company targeting central nervous system (CNS) disorders, develops novel therapies for depression, narcolepsy, and other CNS conditions. Its current ...

US CNS-focused biopharma firm Axsome Therapeutics today announced that the EMERGE Phase III trial of Symbravo (MoSEIC ...